Literature DB >> 21907011

Translation initiator EIF4G1 mutations in familial Parkinson disease.

Marie-Christine Chartier-Harlin1, Justus C Dachsel, Carles Vilariño-Güell, Sarah J Lincoln, Frédéric Leprêtre, Mary M Hulihan, Jennifer Kachergus, Austen J Milnerwood, Lucia Tapia, Mee-Sook Song, Emilie Le Rhun, Eugénie Mutez, Lydie Larvor, Aurélie Duflot, Christel Vanbesien-Mailliot, Alexandre Kreisler, Owen A Ross, Kenya Nishioka, Alexandra I Soto-Ortolaza, Stephanie A Cobb, Heather L Melrose, Bahareh Behrouz, Brett H Keeling, Justin A Bacon, Emna Hentati, Lindsey Williams, Akiko Yanagiya, Nahum Sonenberg, Paul J Lockhart, Abba C Zubair, Ryan J Uitti, Jan O Aasly, Anna Krygowska-Wajs, Grzegorz Opala, Zbigniew K Wszolek, Roberta Frigerio, Demetrius M Maraganore, David Gosal, Tim Lynch, Michael Hutchinson, Anna Rita Bentivoglio, Enza Maria Valente, William C Nichols, Nathan Pankratz, Tatiana Foroud, Rachel A Gibson, Faycal Hentati, Dennis W Dickson, Alain Destée, Matthew J Farrer.   

Abstract

Genome-wide analysis of a multi-incident family with autosomal-dominant parkinsonism has implicated a locus on chromosomal region 3q26-q28. Linkage and disease segregation is explained by a missense mutation c.3614G>A (p.Arg1205His) in eukaryotic translation initiation factor 4-gamma (EIF4G1). Subsequent sequence and genotype analysis identified EIF4G1 c.1505C>T (p.Ala502Val), c.2056G>T (p.Gly686Cys), c.3490A>C (p.Ser1164Arg), c.3589C>T (p.Arg1197Trp) and c.3614G>A (p.Arg1205His) substitutions in affected subjects with familial parkinsonism and idiopathic Lewy body disease but not in control subjects. Despite different countries of origin, persons with EIF4G1 c.1505C>T (p.Ala502Val) or c.3614G>A (p.Arg1205His) mutations appear to share haplotypes consistent with ancestral founders. eIF4G1 p.Ala502Val and p.Arg1205His disrupt eIF4E or eIF3e binding, although the wild-type protein does not, and render mutant cells more vulnerable to reactive oxidative species. EIF4G1 mutations implicate mRNA translation initiation in familial parkinsonism and highlight a convergent pathway for monogenic, toxin and perhaps virally-induced Parkinson disease.
Copyright © 2011 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907011      PMCID: PMC3169825          DOI: 10.1016/j.ajhg.2011.08.009

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  25 in total

1.  MAP-O-MAT: internet-based linkage mapping.

Authors:  X Kong; T C Matise
Journal:  Bioinformatics       Date:  2004-09-16       Impact factor: 6.937

Review 2.  Epidemiology of Parkinson's disease.

Authors:  Lonneke M L de Lau; Monique M B Breteler
Journal:  Lancet Neurol       Date:  2006-06       Impact factor: 44.182

Review 3.  Regulation of translation initiation in eukaryotes: mechanisms and biological targets.

Authors:  Nahum Sonenberg; Alan G Hinnebusch
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

Review 4.  Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance.

Authors:  Chun Zhou; Yong Huang; Serge Przedborski
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 5.  Translation matters: protein synthesis defects in inherited disease.

Authors:  Gert C Scheper; Marjo S van der Knaap; Christopher G Proud
Journal:  Nat Rev Genet       Date:  2007-07-31       Impact factor: 53.242

6.  Requirement of RNA binding of mammalian eukaryotic translation initiation factor 4GI (eIF4GI) for efficient interaction of eIF4E with the mRNA cap.

Authors:  Akiko Yanagiya; Yuri V Svitkin; Shoichiro Shibata; Satoshi Mikami; Hiroaki Imataka; Nahum Sonenberg
Journal:  Mol Cell Biol       Date:  2008-12-29       Impact factor: 4.272

Review 7.  Molecular mechanisms of mTOR-mediated translational control.

Authors:  Xiaoju Max Ma; John Blenis
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04-02       Impact factor: 94.444

8.  Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer.

Authors:  Deborah Silvera; Rezina Arju; Farbod Darvishian; Paul H Levine; Ladan Zolfaghari; Judith Goldberg; Tsivia Hochman; Silvia C Formenti; Robert J Schneider
Journal:  Nat Cell Biol       Date:  2009-06-14       Impact factor: 28.824

Review 9.  Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.

Authors:  Hansruedi Büeler
Journal:  Exp Neurol       Date:  2009-03-18       Impact factor: 5.330

10.  eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy.

Authors:  Francisco Ramírez-Valle; Steve Braunstein; Jiri Zavadil; Silvia C Formenti; Robert J Schneider
Journal:  J Cell Biol       Date:  2008-04-21       Impact factor: 10.539

View more
  104 in total

1.  Xenopus laevis as a Model to Identify Translation Impairment.

Authors:  Amélie de Broucker; Pierre Semaille; Katia Cailliau; Alain Martoriati; Thomas Comptdaer; Jean-François Bodart; Alain Destée; Marie-Christine Chartier-Harlin
Journal:  J Vis Exp       Date:  2015-09-27       Impact factor: 1.355

Review 2.  Language impairment in primary progressive aphasia and other neurodegenerative diseases.

Authors:  D R Rahul; R Joseph Ponniah
Journal:  J Genet       Date:  2019-11       Impact factor: 1.166

Review 3.  Genetics of Parkinson's disease.

Authors:  Christine Klein; Ana Westenberger
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 4.  Role of translation initiation factor 4G in lifespan regulation and age-related health.

Authors:  Amber Howard; Aric N Rogers
Journal:  Ageing Res Rev       Date:  2014-01-03       Impact factor: 10.895

Review 5.  Epigenetic regulation in Parkinson's disease.

Authors:  Catherine Labbé; Oswaldo Lorenzo-Betancor; Owen A Ross
Journal:  Acta Neuropathol       Date:  2016-06-29       Impact factor: 17.088

Review 6.  The genetics of Parkinson's disease: progress and therapeutic implications.

Authors:  Andrew B Singleton; Matthew J Farrer; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

Review 7.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 8.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

9.  DNAJC13 mutations in Parkinson disease.

Authors:  Carles Vilariño-Güell; Alex Rajput; Austen J Milnerwood; Brinda Shah; Chelsea Szu-Tu; Joanne Trinh; Irene Yu; Mary Encarnacion; Lise N Munsie; Lucia Tapia; Emil K Gustavsson; Patrick Chou; Igor Tatarnikov; Daniel M Evans; Frederick T Pishotta; Mattia Volta; Dayne Beccano-Kelly; Christina Thompson; Michelle K Lin; Holly E Sherman; Heather J Han; Bruce L Guenther; Wyeth W Wasserman; Virginie Bernard; Colin J Ross; Silke Appel-Cresswell; A Jon Stoessl; Christopher A Robinson; Dennis W Dickson; Owen A Ross; Zbigniew K Wszolek; Jan O Aasly; Ruey-Meei Wu; Faycal Hentati; Rachel A Gibson; Peter S McPherson; Martine Girard; Michele Rajput; Ali H Rajput; Matthew J Farrer
Journal:  Hum Mol Genet       Date:  2013-11-11       Impact factor: 6.150

10.  Loss of PINK1 attenuates HIF-1α induction by preventing 4E-BP1-dependent switch in protein translation under hypoxia.

Authors:  William Lin; Natasha L Wadlington; Linan Chen; Xiaoxi Zhuang; James R Brorson; Un Jung Kang
Journal:  J Neurosci       Date:  2014-02-19       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.